摘要
背景:DNA拓扑异构酶IIβ (topo IIβ)在神经分化和轴突生长中扮演了一个重要的角色。抑制拓扑异构酶Iiβ在体外和体内的活动导致轴突变短同时增加DNA损伤。在阿尔兹海默病中也涉及这些分子活动,然而,在AD发病机制中拓扑异构酶Iiβ扮演的角色仍需要阐明。 目的:我们的目的是为了调查拓扑异构酶Iiβ在AD发病中与神经受体相关的1蛋白(Nurr1)的联系。 方法:通过从出生后八天大鼠离体体外培养的小脑颗粒神经元(神经元)的纤维状淀粉样蛋白β 1-42 (Aβ1-42)培养48小时建立体外AD模型。拓扑异构酶Iiβ常规角色的Nurr1转录在拓扑异构酶Iiβ沉默CGNs中分析,同时在神经分化的间充质细胞(hMSC)拓扑异构酶Iiβ沉默和过表达。 结果:研究表明Aβ1-42纤维导致基因控制在PS1基因和mRNA水平的测定和tau蛋白的过度磷酸化,都是AD的病理特点。在mRNA和蛋白质水平中拓扑异构酶Iiβ表达显著下降,同时在RNA水平中Nurr1显著下降也被观察到。在所有类型的细胞中,由于拓扑异构酶Iiβ缺乏Nurr1表达都是显著的规律性下降,并且在拓扑异构酶Iiβ过表达hMSCs中上升。 结论:我们的研究发现表明拓扑异构酶Iiβ能够成为一个在低流速信号通路靶点贡献于AD类似疾病。然而,为了阐明AD和拓扑异构酶Iiβ之间更为准确的联系,进一步的研究仍需要在体内实施。
关键词: DNA拓扑异构酶Iiβ,阿尔兹海默病,纤维状淀粉样β 1-42蛋白,轴突生长,原代大鼠小脑颗粒神经元,人骨髓间充质干细胞。
Current Alzheimer Research
Title:Cellular Model of Alzheimer's Disease: Aβ1-42 Peptide Induces Amyloid Deposition and a Decrease in Topo Isomerase IIβ and Nurr1 Expression
Volume: 14 Issue: 6
关键词: DNA拓扑异构酶Iiβ,阿尔兹海默病,纤维状淀粉样β 1-42蛋白,轴突生长,原代大鼠小脑颗粒神经元,人骨髓间充质干细胞。
摘要: Background: DNA topoisomerase IIβ (topo IIβ) plays a crucial role in neural differentiation and axonogenesis. Inhibition of topo IIβ activity in vitro and in vivo results in shorter axons and increased DNA damage. These molecular events also involve in Alzheimer's disease (AD); however, the role of topo IIβ in the pathogenesis of AD remains to be elucidated.
Objectives: We aimed to investigate the role of topo IIβ association with Nuclear receptor related 1 protein (Nurr1) in the onset of AD. Methods: In vitro AD model was established by the incubation of fibrillar amyloid-β 1-42 (Aβ1-42) for 48 hours with cultured cerebellar granule neurons (CGNs) isolated from post-natal eight-day rats. The regulatory role of topo IIβ on the transcription of Nurr1 was analyzed in topo IIβ silenced CGNs, and also topo IIβ silenced and overexpressed in a neurally-differentiated human mesenchymal (hMSC) cell line. Results: Aβ1-42 fibrils led to the upregulation of Presenilin1 and Cofilin1 genes as measured at mRNA levels and hyperphosphorylation of tau protein, all are distinctive characteristics of AD pathology. A significant decrease in topo IIβ expression at mRNA and protein levels and Nurr1 at mRNA level was also observed. In both cell types, Nurr1 expression was dramatically down-regulated due to topo IIβ deficiency, and was increased in topo IIβ overexpressing hMSCs. Conclusion: Our findings suggest that topo IIβ could be a down-stream target of signaling pathways contributing to AD-like pathology. However, further studies must be carried out in vivo to elucidate the precise association topo IIβ with AD.Export Options
About this article
Cite this article as:
Cellular Model of Alzheimer's Disease: Aβ1-42 Peptide Induces Amyloid Deposition and a Decrease in Topo Isomerase IIβ and Nurr1 Expression, Current Alzheimer Research 2017; 14 (6) . https://dx.doi.org/10.2174/1567205014666170117103217
DOI https://dx.doi.org/10.2174/1567205014666170117103217 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prolactin and Blood-Brain Barrier Permeability
Current Neurovascular Research Medicinal Use of Lincosamides and Microbial Resistance to Them
Anti-Infective Agents in Medicinal Chemistry Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Severe Hemorrhagic Cystitis Associated with BK Polyoma Virus Infection Following Lung Transplantation
Current Respiratory Medicine Reviews Rho as a Target to Promote Repair: Translation to Clinical Studies with Cethrin
Current Pharmaceutical Design Evaluation of Vancoplus Versus Ceftriaxone Against Cephalosporin Resistance MRSA Strain in Experimental Meningitis Model
Cardiovascular & Hematological Disorders-Drug Targets Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets Antifungal Proteins: Potent Candidate for Inhibition of Pathogenic Fungi
Current Bioactive Compounds Smart Drug-Delivery Systems for Cancer Nanotherapy
Current Drug Targets Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Therapeutic Approaches to the Challenge of Neuronal Ceroid Lipofuscinoses
Current Pharmaceutical Biotechnology Gene Therapy of Chronic Pain
Current Gene Therapy Recent Developments in Therapeutic Approaches for Lysosomal Storage Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Systematic Review
Current Pediatric Reviews Endotoxin Neutralizing Peptides
Current Topics in Medicinal Chemistry Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research Editorial (Thematic Issue: MiRNAcles in the Brain: What to Wish and What to Fear)
CNS & Neurological Disorders - Drug Targets In Vitro Blood-Brain Barrier Models – Latest Advances and Therapeutic Applications in a Chronological Perspective
Mini-Reviews in Medicinal Chemistry Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult
Current Vascular Pharmacology Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews